NIH Consensus Development Conference: 
Management of Hepatitis B
October 20-22, 2008

Videocast Archive

Below please find the archived videocast, separated by conference question.  Viewing the videocast requires RealPlayer software, which can be downloaded free of charge from the NIH videocast website.  Video will launch in a separate window.

If you are interested in presenting the videos at conferences or grand rounds, please contact us to arrange for file transfer.

 i. Opening Remarks

• Opening Remarks
  Griffin P. Rodgers, M.D.
• Charge to the Panel
  Susan Rossi, Ph.D., M.P.H.
• Conference Overview and Panel Activities
  Michael F. Sorrell, M.D.

I. What is the Current Burden of Hepatitis B?

• Hepatitis B Virus and the Diseases It Causes abstract
  T. Jake Liang, M.D.
• Evaluation of the Patient With Hepatitis B abstract
  Eugene R. Schiff, M.D., M.A.C.P., F.R.C.P., M.A.C.G., A.G.A.F.
• Epidemiology of Hepatitis B abstract
  W. Ray Kim, M.D., M.Sc., M.B.A.
• Recommendations for Identification and Public Health Management of Persons With Chronic Hepatitis B Virus Infection abstract
  Cindy M. Weinbaum, M.D., M.P.H.

II. What is the Natural History of Hepatitis B?

• Introduction to the Natural History of Chronic Hepatitis B abstract
  Brian J. McMahon, M.D.
• Hepatitis B and Liver Cancer abstract
  Adrian M. Di Bisceglie, M.D., F.A.C.P.
• Liver Biopsy Findings in Chronic Hepatitis B abstract
  David E. Kleiner, M.D., Ph.D.
• HBV DNA Levels and Outcomes in Chronic Hepatitis B abstract
  Chien-Jen Chen, Sc.D., M.P.H.
• Evidence-Based Practice Center Presentation I: Population Characteristics and Clinical Features Associated With Hepatitis B and Predictability of Hepatocellular Carcinoma, Liver Failure, Cirrhosis, Liver-Related Death, and All-Cause Mortality abstract
  Brent C. Taylor, Ph.D., M.P.H.

III. What are the Benefits and Risks of the Current Therapeutic Options for Hepatitis B?

• Overview: Benefits and Risks of Treatment for Chronic Hepatitis B abstract
  Jenny Heathcote, M.D., FRCPC
• Benefits and Risks of Interferon Therapy for Hepatitis B Benefits and Risks of Interferon Therapy for Hepatitis B abstract
  Robert P. Perrillo, M.D.
• Benefits and Risks of Nucleos(t)ide Analogues for Hepatitis B abstract
  Jules L. Dienstag, M.D.
• Benefits and Risks of Combination Therapy for Hepatitis B abstract
  Norah A. Terrault, M.D., M.P.H.
• Evidence-Based Practice Center Presentation II: Efficacy/Effectiveness of Interferon Therapy, Oral Therapy, and Various Combinations in Treating Hepatitis B abstract
  Timothy J. Wilt, M.D., M.P.H.

IV. Which Persons With Hepatitis B Should Be Treated?

• Indications for Therapy in Hepatitis B abstract
  Anna S.F. Lok, M.D.
• HIV/HBV Co-infection abstract
  Chloe L. Thio, M.D.
• Special Populations and Hepatitis B abstract
  Marion G. Peters, M.D., M.B.B.S.
• Reactivation of Hepatitis B abstract
  Jay H. Hoofnagle, M.D.
• Evidence-Based Practice Center Presentation III: Differences in Efficacy/Effectiveness of Treatments for Subpopulations With Hepatitis B Virus and the Use of Surrogate Endpoints as Predictors of Long Term Resolution or Slowed Progression of Disease abstract
  Aasma Shaukat, M.D., M.P.H.

V. What Measures Are Appropriate To Monitor Therapy and Assess Outcomes?

• Monitoring During and After Antiviral Therapy for Hepatitis B abstract
  Raymond T. Chung, M.D.
• Antiviral Resistance and Hepatitis B Therapy abstract
  Marc G. Ghany, M.D.
• Side Effects of Long-Term Antiviral Therapy for Hepatitis B abstract
  Robert J. Fontana, M.D.

Draft Conference Statement

• Final Panel Statement PDF or HTML (coming soon)

Press conference

• NIH Press Release

Contact Consensus Program | Privacy Notice | Disclaimer | Accessibility | Contact NIH